Bausch Health Companies Inc. (NYSE:BHC) Receives Consensus Recommendation of “Hold” from Analysts

Bausch Health Companies Inc. (NYSE:BHC) has been assigned a consensus rating of “Hold” from the seven ratings firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $7.75.

Several equities analysts recently issued reports on BHC shares. StockNews.com raised Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Friday, October 25th. Royal Bank of Canada boosted their price target on Bausch Health Companies from $10.00 to $11.00 and gave the company a “sector perform” rating in a report on Friday, November 1st. Evercore ISI raised Bausch Health Companies to a “hold” rating in a research note on Tuesday, October 15th. Piper Sandler downgraded shares of Bausch Health Companies from a “neutral” rating to an “underweight” rating and dropped their price objective for the company from $9.00 to $3.00 in a research note on Friday, August 2nd. Finally, Jefferies Financial Group reduced their price target on shares of Bausch Health Companies from $13.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday, August 7th.

Insider Buying and Selling

In related news, EVP Seana Carson sold 13,370 shares of the firm’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $6.21, for a total transaction of $83,027.70. Following the completion of the transaction, the executive vice president now owns 435,198 shares of the company’s stock, valued at $2,702,579.58. This trade represents a 2.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 8.12% of the company’s stock.

Institutional Investors Weigh In On Bausch Health Companies

Several large investors have recently modified their holdings of the stock. Headlands Technologies LLC acquired a new position in shares of Bausch Health Companies in the second quarter worth about $35,000. MQS Management LLC purchased a new position in Bausch Health Companies during the 2nd quarter valued at about $71,000. Certuity LLC purchased a new stake in shares of Bausch Health Companies in the second quarter worth approximately $75,000. Bfsg LLC boosted its holdings in shares of Bausch Health Companies by 46.7% during the second quarter. Bfsg LLC now owns 11,450 shares of the company’s stock worth $80,000 after purchasing an additional 3,643 shares during the period. Finally, Kendall Capital Management purchased a new position in Bausch Health Companies during the second quarter valued at approximately $87,000. 78.65% of the stock is owned by institutional investors.

Bausch Health Companies Stock Down 0.8 %

NYSE:BHC opened at $7.89 on Wednesday. The firm’s fifty day simple moving average is $8.39 and its 200-day simple moving average is $7.11. The stock has a market cap of $2.90 billion, a PE ratio of -16.44 and a beta of 0.74. Bausch Health Companies has a fifty-two week low of $3.96 and a fifty-two week high of $11.46.

Bausch Health Companies (NYSE:BHC) last issued its earnings results on Wednesday, October 30th. The company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.10. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 755.86%. The company had revenue of $2.51 billion for the quarter, compared to analyst estimates of $2.42 billion. During the same period in the prior year, the business posted $1.03 earnings per share. The firm’s revenue for the quarter was up 12.2% compared to the same quarter last year. Equities analysts anticipate that Bausch Health Companies will post 3.74 earnings per share for the current year.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.